Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for February 2009
February 2, 2009
- Lipitor Significantly Reduced hsCRP Levels in Patients with Stable Coronary Artery Disease, According to New Study
- Unigene Clinical Study Suggests Novel Treatment Regimen for Osteoporosis
- Ligand Announces Phase IIb Results With DARA
- Hospira's Precedex Phase IV Study Published in the Journal of the American Medical Association
- Mayo Clinic Study Finds Younger Men With Erectile Dysfunction at Double Risk of Heart Disease
- Newer Medication May Offer Advantages Over Agents Commonly Used For Sedation of Intensive Care Unit Patients
February 3, 2009
- InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
- Phase III Study Showed Tarceva in Combination With Avastin as First-Line Maintenance Therapy Improved Progression-Free Survival in Advanced Lung Cancer
- InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
- Merck’s Safinamide Significantly Improved Motor Function in Patients with Advanced Parkinson’s Disease in a Phase III Pivotal Trial
- Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant
- Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
- Senesco Announces Results of Pre-Clinical Efficacy, Toxicology and Dose Ranging Studies for Multiple Myeloma Therapeutic Candidate
- Medgenics Announces Positive Data From Phase I/II Clinical Trial of EPODURE Treatment of Anemia in Chronic Kidney Disease
- Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine
- PhytoMedical's Patented Anti-Cancer Compound Eradicates Tumor in Successful In-Vivo Tests against Human Brain Cancer
- AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences
February 4, 2009
- Allos Therapeutics Announces Final Results from Pivotal PROPEL Trial of Pralatrexate in Patients with Peripheral T-cell Lymphoma
- OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
- Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
- Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
- GSK and Theravance Announce Positive Phase 2b Results for Once-daily Fluticasone Furoate in the Treatment of Asthma
- Positive Data From Lung Study May Lead to First FDA Approved Treatment for Pulmonary Fibrosis
February 5, 2009
- New Evidence of Hormone Therapy Causing Breast Cancer, Stanford Professor Says
- BioDelivery Sciences Announces Initial Results of Phase 1 Clinical Study of Bioral Amphotericin B
- Interim Results From the MIRACEL Study Now Reported In the Renal Anaemia Disease Knowledge Centre at EPG Online
- Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
- Physicians from the Burzynski Clinic Present Initial Results of Combination Gene-Targeting Therapies on Advanced Pancreatic and Liver Cancers
- Minocycline/Rifampin-Impregnated Catheters Proven Clinically Effective in Preventing and Combating Potentially Fatal Bloodstream Infections in Two New Studies
- HemCon Medical Technologies, Inc. Announces Promising Results from Live Nail Infection Anti-Fungal Study Technology Platform Offers Tested Solution to Fungal Care Market
February 6, 2009
February 9, 2009
- M. D. Anderson Study Finds Pregnancy Has No Impact on Breast Cancer Survival, Does Delay Treatment, Diagnosis
- Benitec Limited (ASX:BLT) City of Hope Human HIV Trial Update
- Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study
- Anti-HIV Gel Shows Promise in Large-Scale Study in Women
- ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
- MS Patients Treated with Tysabri Remain Free of Disease Activity for Two Years, According to Data Published in the Lancet Neurology
- EntreMed Presents Initial Clinical Results for ENMD-2076
- New PRO2000 HIV-Prevention Findings Important Milestone on Path Toward Development of Effective Vaginal Microbicide
- Winston Pharmaceuticals Announces Positive Top-line Results of Phase I Clinical Trial of Civamide Patch
- Prism Pharmaceuticals' Study of Injectable Clopidogrel Accepted for Presentation at the American College of Cardiology
February 10, 2009
- ConjuChem reports final data confirming PC-DAC:Exendin-4 lowers glucose and weight in Phase II diabetes trials
- Starpharma Holdings Limited (ASX:SPL) Topical Microbicide Field Receives a Boost with Human Efficacy Result
- Theratechnologies presents data at CROI
- Phase III Studies Showed Isentress in Combination Therapy Provided Significant Viral Load Reductions Through 96 Weeks in Treatment-Experienced Patients with Triple-Class Resistant HIV
- Data from Isentress, Merck's HIV Integrase Inhibitor, in Patients Whose HIV is Controlled on a Lopinavir/Ritonavir-Based Therapy Presented at the 16th Conference on Retroviruses and Opportunistic Infections
- Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)
- Study Demonstrates Restylane Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
- Nature Reviews Publishes Article About Jennerex's Multi-Mechanistic Cancer Therapeutic
February 11, 2009
- Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
- Regenocyte Therapeutic Reports Successful Treatment of Cardiomyopathy with Stem Cells
- CLSI Publishes Guideline for Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data
- Phase 1 Trial of Quadramet in Combination with Velcade Shows Positive Results
- Study Suggests New Treatment Approach May be Needed for Management of Depression in Some People With Bipolar Disorder
February 12, 2009
- La Jolla Pharmaceutical Company Announces Negative Results of Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial
- Zometa Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
- Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile
- Alnylam and Collaborators Present Data from Multiple Pre-Clinical and Clinical Programs at RNAi Keystone Symposium
- New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq (dronedarone) in Atrial Fibrillation
- Osiris Reports Positive Two-Year Data on Stem Cell Treatment for Acute Myocardial Infarction
- GenoMed's Results Supported by Canadian Study: Dose is Key!
- Hope for 14 Million Rosacea Sufferers: Pyratine-XR Study to be Presented at South Beach Symposium
- Charleston Conducts Evaluation of an Opioid Symptoms Questionnaire
- Promising medical news for atrial fibrillation patients
February 13, 2009
- Vical Presents Pandemic Influenza Vaccine Results and Outlook At WHO Meeting
- Study Reveals Avosentan May Slow Progression of Diabetic Kidney Disease
February 17, 2009
- Shionogi Announces Positive Top-Line Efficacy Results from Year-Long Studies of Velneperit, a Novel NPY Y5 Receptor Antagonist Being Investigated for the Treatment of Obesity
- Update of Long-Term Data on Brain Cancer Patients Receiving DCVax-Brain Continues to Show Striking Improvements in Delay of Disease and Survival
- IMPACT Study Demonstrates That Longer Prophylactic Therapy With Valcyte (Valganciclovir Hydrochloride Tablets) Increases Protection Against CMV - the Most Serious Viral Infection Affecting Transplant Patients
- BioSante Pharmaceuticals, Inc. Presents LibiGel Clinical and Market Information at ISSWSH Conference
- Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference
- Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinson's Disease
- Pluristem Therapeutics to Present at Italian CREM Workshop Focused on Placental-Derived Cells
- Newly Published Menopause Study: 'Bioidentical' and FDA-Approved Divigel (estradiol gel) 0.1 Percent Safe and Effective Treatment for Moderate to Severe Hot Flashes Associated With Menopause
- University of Ottawa Heart Institute Scientists Unlock Mechanism That Turns on Weight-Loss Gene
- Transgene Confirms Longer Survival For Patients Treated With Tg4010 In Its Ongoing Phase IIb Non-Small Cell Lung Cancer Trial
- Tracon Pharmaceuticals to Present Clinical Stage Programs at AACR 2009
- Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C
- Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C
February 18, 2009
- High-Throughput Genotyping of AML Patients for a Key Immune Receptor May Significantly Improve Treatment Outcome
- Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology
- Compared To Standard Therapies, Pixantrone Decreases Time To Achieve Complete Remission By 47% In Relapsed Aggressive Non-Hodgkin's Lymphoma
- VGX Pharmaceuticals Proprietary DNA Vaccines Delivered with Electroporation Achieve Immune Responses Superior to Recombinant Adenovirus Serotype 5 (Ad5) Vectors
- Phase III Results in SOFIA Study of NPL-2008
- iCo Therapeutics Oral Amphotericin B Published in Leading Journal
- Lancet Oncology: Epigenetic drug doubles survival in patients with 'preleukemia,' MDS
- Stanford Scientists Identify Drug to Treat Opioid Addiction
- Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkin's Lymphoma
- KanekaQH Ubiquinol Dramatically Boosts Ejection Fraction in Patients With Late-Stage Congestive Heart Failure
- Data Published in The Lancet Oncology Further Substantiates VIDAZA's Extended Survival Benefit for MDS Patients
February 19, 2009
- Research Brings New Hope to Multiple Sclerosis Patients
- Kidney Disease Affects Response to Blood Thinner
- New England Journal of Medicine Publishes Results from Boston Scientific's Landmark SYNTAX Trial
- Crestor Cuts Risk of Stroke by Nearly Half in JUPITER Study
February 20, 2009
- EPIX Pharmaceuticals to Present Preclinical Data for Two Programs at Keystone Symposia
- ImQuest Presentations at CROI Report Significant Advances in Therapeutic and Microbicide Product Development Programs
- Study of Genzyme Oral Compound for Gaucher Disease Meets Primary Endpoint
- UCB Announces Top-Line Outcomes for Proof-of-Concept Studies
February 23, 2009
- Bavarian Nordic A/S (DK) - Bavarian Nordic updates on Phase I/II studies with breast cancer vaccine
- EpiCept Announces EPC2407 Generic Name is Crinobulin
- Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections
- Clinical Results with RegeneRx's Ophthalmic Drug Candidate Subject of Oral Presentation at 2009 ARVO Meeting
- VGX Pharmaceuticals Avian Influenza DNA Vaccine Delivered with Electroporation Provides 100% Protection of Non-Human Primates
- Data on VELCADE (Bortezomib) for Injection Based Therapies to be Presented at the International Myeloma Workshop
February 24, 2009
- AstraZeneca's Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
- Orion Corporation (FI) - Orion: Primary Objective of STRIDE-PD Study Was Not Achieved
- Optimer Pharmaceuticals Announces Positive Results from Second Phase 3 Study of Prulifloxacin for Infectious Diarrhea in Travelers
- Tekmira Presents Data Demonstrating Further Increases in SNALP Potency
- MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints
- PharmAthene Presents Data for SparVax and Valortim, a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting
February 25, 2009
- Adipose-Derived Stem and Regenerative Cells Prevent Mortality and Reduce Kidney Damage in Preclinical Study
- Bavarian Nordic reports further data on Prostvac
- Avigen Announces Positive Data for AV411 in Pain Relief and Drug Addiction
- PharmAthene Anthrax Protection Data Presented at ASM Biodefense Disease Meeting
- AVEO Pharmaceuticals' Oral, Triple VEGF Receptor Inhibitor AV-951 Shows Robust Activity in Patients with Advanced Kidney Cancer
- Hawaii Biotech Reports Phase 1 Results for West Nile Virus Vaccine
- Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
- Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
- New Cancer Treatment Stops Aggressive Sarcomas
- Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients
February 26, 2009
- CPEX Pharmaceuticals Announces Completion of Phase 2 Trial for Urology Drug by Serenity Pharmaceuticals
- Optimer Pharmaceuticals Announces Publication in Peer-Reviewed Journal about Prulifloxacin's Antibacterial Activity against Infectious Diarrhea Producing Bacteria
- Archimedes Pharma Announces Successful Proof-of-Concept Results on Two Intranasal Development Projects
- Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
- DeveloGen AG (DE) - DeveloGen Reports Positive Phase 1 Clinical Trial Results for DG3173
- RegeneRx Updates on Phase II Venous Stasis Trial
- Crucell N.V. (NL) - Crucell's Revolutionary Antibody for Universal Therapy Against Flu
- Reproductive Factors May Protect Women from Parkinson's Disease
- Research Finding Could Revolutionize Asthma Treatment
February 27, 2009
- Safety and Overall Survival Data in Docetaxel-Refractory Patients Enrolled in the Satraplatin SPARC Trial Being Presented at 2009 ASCO Genitourinary Cancers Symposium
- Safety and Overall Survival Data in Docetaxel-Refractory Patients Enrolled in the Satraplatin SPARC Trial Being Presented at 2009 ASCO Genitourinary Cancers Symposium
- BioInvent Presents Positive Preclinical Data for BI-505 in Myeloma
- Diabetes Patients With High Triglycerides and Low HDL Cholesterol get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study
- Mesoblast Limited (ASX:MSB) Presents Positive Adult Stem Cell Results To American Academy of Orthopedic Surgeons (AAOS)
- Cell Genesys Announces Final Results from Phase 3 Program of GVAX Immunotherapy for Prostate Cancer
- Cougar Biotechnology Announces Presentation of Positive CB7630 (Abiraterone Acetate) Phase II Data at ASCO 2009 Genitourinary Cancers Symposium
- Data Published in The Lancet Show Fampridine-SR Improved Walking Ability in People with Multiple Sclerosis
- Novagali Pharma Presents Results of its Innovative Latanoprost Formulation for Glaucoma
- Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer
